Pfizer: ‘Dropped preclinical programs do not change commitment to biosimilars
In the latest example of a Big Biopharma reducing its biosimilar presence, Pfizer has abandoned five of its preclinical programs. The decision is part of an R&D review set to cut 150 jobs in Illinois and India. In November 2018, Bioprocess Insider reported claims that Big Pharma is set to exi ...
The US Biomedical Advanced Research and Development Authority (BARDA) has exercised a second option in its smallpox vaccine contract with Bavaria ...
It took Eli Lilly 18 days from expressing its interest in Loxo Oncology to executing an $8 billion merger agreement. Being a “significant premi ...
Boehringer Ingelheim has begun an expansion at its biomanufacturing facility in Shanghai as it looks to tap the “great potential in China.”
...
Sanofi has licensed the plug-and-play BiXAb platform to generate multi-specific antibodies. The deal validates the technology and will help fund ...
Recent Tweets
-
RT @Dan5tanton: It took Eli Lilly 18 days from expressing its interest in Loxo Oncology to executing an $8 billion merger agreement… https://t.co/8jdTN4yJSb
3 days ago
-
RT @Dan5tanton: In the latest example of a Big Biopharma reducing its biosimilar presence, Pfizer has abandoned five of its preclin… https://t.co/SZNtQSUaiY
4 days ago
-
RT @Dan5tanton: After raising $324 million last year, @AllogeneTx says it is planning to construct a cell therapy manufacturing fa… https://t.co/a5QS2fiPfZ
6 days ago
-
RT @Dan5tanton: #CDMO Lonza upping mammalian PD and small-scale cGMP manufacturing capabilities through multi-million pound investm… https://t.co/ubG8c1CJkQ
1 week ago
